for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Constellation Pharmaceuticals Inc

CNST.OQ

Latest Trade

33.82USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

17.00

 - 

39.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
33.82
Open
--
Volume
--
3M AVG Volume
27.55
Today's High
--
Today's Low
--
52 Week High
39.17
52 Week Low
17.00
Shares Out (MIL)
47.91
Market Cap (MIL)
1,614.25
Forward P/E
-9.53
Dividend (Yield %)
--

Next Event

Q2 2021 Constellation Pharmaceuticals Inc Earnings Release

Latest Developments

More

Morphosys To Buy Constellation Pharmaceuticals

Constellation Pharmaceuticals Announces Q1 Loss Per Share Of $0.84

Constellation Pharmaceuticals Announces Fourth-Quarter And Full-Year 2020 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Industry

Biotechnology & Drugs

Contact Info

215 1st St Ste 200

CAMBRIDGE, MA

02142-1293

United States

+1.617.7140555

https://www.constellationpharma.com/

Executive Leadership

Mark A. Goldsmith

Independent Chairman of the Board

Jigar Raythatha

President, Chief Executive Officer, Director

Emma Reeve

Chief Financial Officer, Senior Vice President, Treasurer

Patrick Trojer

Chief Scientific Officer

Karen Higgins Valentine

Chief Legal Officer, General Counsel

Key Stats

2.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-5.000

2019

-3.040

2020

-2.810

2021(E)

-3.547
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.28
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-38.57
Return on Equity (TTM)
-36.35

Latest News

Latest News

UPDATE 1-Morphosys to acquire Constellation Pharma in $1.7 bln deal

Morphosys on Wednesday said it will acquire U.S. cancer specialist Constellation Pharmaceuticals for $1.7 billion to add an advanced experimental cancer drug and broaden its drug development, prompting a slump in its shares.

Morphosys to acquire Constellation Pharmaceuticals in $1.7 billion deal

Morphosys on Wednesday said it will acquire U.S. cancer specialist Constellation Pharmaceuticals in a $1.7 billion deal that will enable the German biotech firm to add two final-stage cancer drugs to its portfolio.

BRIEF-Constellation Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* CONSTELLATION PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Great Point Partners LLC Reports 5.5% Passive Stake In Constellation Pharmaceuticals As Of May 26

* GREAT POINT PARTNERS LLC REPORTS 5.5% PASSIVE STAKE IN CONSTELLATION PHARMACEUTICALS AS OF MAY 26 - SEC FILING Source text: (https://bit.ly/30cRwMB) Further company coverage:

BRIEF-Constellation Pharmaceuticals Provides Update Of Preliminary Data For CPI-0610 In Three EHA Abstracts

* CONSTELLATION PHARMACEUTICALS PROVIDES UPDATE OF PRELIMINARY DATA FOR CPI-0610 IN THREE EHA ABSTRACTS

BRIEF-Constellation Pharmaceuticals Reports Q1 Loss Per Share $0.61

* CONSTELLATION PHARMACEUTICALS ANNOUNCES FIRST-QUARTER 2020 FINANCIAL RESULTS

BRIEF-Constellation Pharma Says Election Of Richard Levy Brings Size Of Board To Eight Members

* CONSTELLATION PHARMACEUTICALS INC - ELECTION OF RICHARD LEVY BRINGS SIZE OF BOARD TO EIGHT MEMBERS Source text: [https://bit.ly/2UJzheF] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Constellation Pharmaceuticals Announces Appointment Of Dr. Richard Levy To Board Of Directors

* CONSTELLATION PHARMACEUTICALS ANNOUNCES APPOINTMENT OF DR. RICHARD LEVY TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Constellation Pharmaceuticals Announces Q4 Loss Per Share $0.69

* CONSTELLATION PHARMACEUTICALS ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up